Johnson & Johnson Invests $2B in New State-of-the-Art Manufacturing Facility in North Carolina Read more
FDA Expands Approval of AJOVY as First Anti-CGRP Preventive for Pediatric Episodic Migraine Read more
FDA Accepts Bristol Myers Squibb’s Priority Review for Breyanzi in Relapsed/Refractory Marginal Zone Lymphoma Read more